| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Adrenal Insufficiency | 7 | 2020 | 190 | 3.37 | Why? |
| Phosphodiesterase 5 Inhibitors | 5 | 2020 | 104 | 1.88 | Why? |
| Hormone Replacement Therapy | 3 | 2020 | 146 | 1.56 | Why? |
| Hypogonadism | 4 | 2018 | 196 | 1.55 | Why? |
| Hydrocortisone | 7 | 2020 | 1790 | 1.46 | Why? |
| Cyclic Nucleotide Phosphodiesterases, Type 5 | 4 | 2020 | 24 | 1.40 | Why? |
| Glucocorticoids | 6 | 2020 | 4431 | 1.09 | Why? |
| Receptors, Androgen | 2 | 2021 | 212 | 0.94 | Why? |
| Cyclic GMP | 2 | 2020 | 50 | 0.88 | Why? |
| Testosterone | 6 | 2021 | 596 | 0.86 | Why? |
| Human Growth Hormone | 2 | 2019 | 120 | 0.85 | Why? |
| Adrenal Gland Neoplasms | 2 | 2018 | 70 | 0.84 | Why? |
| Angiopoietin-1 | 1 | 2019 | 25 | 0.81 | Why? |
| Somatostatin | 1 | 2019 | 49 | 0.78 | Why? |
| Endocrinology | 2 | 2020 | 252 | 0.78 | Why? |
| CLOCK Proteins | 1 | 2018 | 24 | 0.75 | Why? |
| Neovascularization, Physiologic | 1 | 2019 | 160 | 0.72 | Why? |
| Acromegaly | 1 | 2019 | 79 | 0.72 | Why? |
| Thyroid Dysgenesis | 1 | 2016 | 4 | 0.68 | Why? |
| Cushing Syndrome | 4 | 2020 | 76 | 0.67 | Why? |
| Parathyroid Glands | 1 | 2016 | 27 | 0.66 | Why? |
| Endocrine System Diseases | 1 | 2020 | 282 | 0.62 | Why? |
| Pituitary-Adrenal System | 3 | 2020 | 135 | 0.61 | Why? |
| Sildenafil Citrate | 4 | 2019 | 66 | 0.59 | Why? |
| Circadian Rhythm | 2 | 2018 | 607 | 0.59 | Why? |
| Hypothalamo-Hypophyseal System | 3 | 2020 | 187 | 0.57 | Why? |
| Steroids | 1 | 2020 | 904 | 0.54 | Why? |
| Nitric Oxide | 2 | 2020 | 769 | 0.53 | Why? |
| Checklist | 1 | 2018 | 714 | 0.47 | Why? |
| Myocytes, Cardiac | 4 | 2018 | 804 | 0.44 | Why? |
| Lymphadenopathy | 1 | 2016 | 444 | 0.41 | Why? |
| Immune System | 1 | 2018 | 1479 | 0.36 | Why? |
| Leukocytes, Mononuclear | 1 | 2018 | 2115 | 0.36 | Why? |
| Gonadal Steroid Hormones | 3 | 2020 | 328 | 0.35 | Why? |
| Monocytes | 2 | 2019 | 2978 | 0.34 | Why? |
| Drug Administration Schedule | 3 | 2018 | 2324 | 0.32 | Why? |
| Testis | 2 | 2019 | 566 | 0.26 | Why? |
| Emergency Medical Services | 1 | 2020 | 3557 | 0.25 | Why? |
| Patient Selection | 1 | 2018 | 4560 | 0.25 | Why? |
| Octreotide | 2 | 2019 | 56 | 0.24 | Why? |
| Thyroid Neoplasms | 2 | 2018 | 422 | 0.24 | Why? |
| Macrophage Migration-Inhibitory Factors | 1 | 2002 | 39 | 0.24 | Why? |
| Age of Onset | 3 | 2018 | 557 | 0.23 | Why? |
| Cyclic AMP Response Element Modulator | 2 | 2018 | 3 | 0.23 | Why? |
| Diabetes Mellitus, Type 2 | 2 | 2019 | 6166 | 0.22 | Why? |
| Biomarkers | 4 | 2018 | 23361 | 0.21 | Why? |
| Leydig Cell Tumor | 1 | 2019 | 4 | 0.21 | Why? |
| Receptors, Somatotropin | 1 | 2019 | 8 | 0.21 | Why? |
| P-Selectin | 1 | 2021 | 224 | 0.20 | Why? |
| Receptor, TIE-2 | 1 | 2019 | 42 | 0.20 | Why? |
| Orchiectomy | 1 | 2019 | 63 | 0.20 | Why? |
| Circadian Rhythm Signaling Peptides and Proteins | 1 | 2018 | 7 | 0.19 | Why? |
| Immunity, Innate | 1 | 2017 | 6570 | 0.19 | Why? |
| Cyclic Nucleotide Phosphodiesterases, Type 2 | 1 | 2018 | 2 | 0.19 | Why? |
| Anti-Mullerian Hormone | 1 | 2019 | 35 | 0.19 | Why? |
| Contraindications, Drug | 1 | 2020 | 281 | 0.19 | Why? |
| Penile Erection | 1 | 2019 | 58 | 0.19 | Why? |
| Fertility Preservation | 1 | 2020 | 121 | 0.19 | Why? |
| Diagnostic Techniques, Endocrine | 1 | 2018 | 12 | 0.19 | Why? |
| Andrology | 1 | 2020 | 126 | 0.19 | Why? |
| Cell Tracking | 1 | 2018 | 10 | 0.19 | Why? |
| Addison Disease | 1 | 2018 | 24 | 0.19 | Why? |
| Carcinoid Tumor | 1 | 2018 | 46 | 0.19 | Why? |
| Peptides | 2 | 2021 | 2513 | 0.19 | Why? |
| Dextrans | 1 | 2018 | 35 | 0.18 | Why? |
| Adrenal Hyperplasia, Congenital | 1 | 2018 | 24 | 0.18 | Why? |
| Anti-Inflammatory Agents | 1 | 2017 | 6153 | 0.18 | Why? |
| Carcinoma, Neuroendocrine | 1 | 2018 | 57 | 0.18 | Why? |
| Glucose Tolerance Test | 1 | 2019 | 238 | 0.18 | Why? |
| Testicular Neoplasms | 1 | 2019 | 91 | 0.18 | Why? |
| Fetal Heart | 1 | 2018 | 46 | 0.18 | Why? |
| Cholesterol, LDL | 2 | 2019 | 499 | 0.18 | Why? |
| Selenomethionine | 1 | 2017 | 9 | 0.18 | Why? |
| Bone Morphogenetic Protein 7 | 1 | 2017 | 5 | 0.18 | Why? |
| Sexual Dysfunction, Physiological | 1 | 2019 | 89 | 0.18 | Why? |
| Cholesterol | 2 | 2019 | 660 | 0.17 | Why? |
| Pituitary Neoplasms | 1 | 2019 | 130 | 0.17 | Why? |
| Foscarnet | 1 | 2017 | 13 | 0.17 | Why? |
| Thyroid Carcinoma, Anaplastic | 1 | 2017 | 16 | 0.17 | Why? |
| Spermatozoa | 1 | 2020 | 244 | 0.17 | Why? |
| Pheochromocytoma | 1 | 2017 | 32 | 0.17 | Why? |
| Peptides, Cyclic | 1 | 2019 | 223 | 0.17 | Why? |
| Diabetic Cardiomyopathies | 1 | 2018 | 79 | 0.17 | Why? |
| Staining and Labeling | 1 | 2018 | 169 | 0.17 | Why? |
| Insulin-Like Growth Factor I | 1 | 2017 | 119 | 0.16 | Why? |
| Hyperparathyroidism | 1 | 2016 | 38 | 0.16 | Why? |
| Growth Disorders | 1 | 2017 | 91 | 0.16 | Why? |
| Adenoma | 1 | 2019 | 215 | 0.16 | Why? |
| Cardiomegaly | 1 | 2017 | 96 | 0.16 | Why? |
| Triglycerides | 1 | 2019 | 478 | 0.16 | Why? |
| Cryopreservation | 1 | 2020 | 464 | 0.16 | Why? |
| Glucose | 2 | 2018 | 573 | 0.16 | Why? |
| Placebos | 1 | 2019 | 629 | 0.16 | Why? |
| Diabetes Mellitus, Experimental | 1 | 2018 | 192 | 0.15 | Why? |
| Cholesterol, HDL | 1 | 2019 | 439 | 0.15 | Why? |
| Regional Blood Flow | 1 | 2016 | 172 | 0.15 | Why? |
| Behavior Therapy | 1 | 2019 | 235 | 0.15 | Why? |
| Computer Systems | 1 | 2016 | 255 | 0.15 | Why? |
| Alleles | 1 | 2021 | 1557 | 0.14 | Why? |
| Thyroxine | 1 | 2017 | 250 | 0.14 | Why? |
| Male | 29 | 2021 | 367725 | 0.14 | Why? |
| Cardiovascular Diseases | 2 | 2018 | 11497 | 0.14 | Why? |
| Vascular Stiffness | 1 | 2018 | 264 | 0.14 | Why? |
| Nephrotic Syndrome | 1 | 2017 | 146 | 0.14 | Why? |
| Hypothyroidism | 1 | 2017 | 239 | 0.14 | Why? |
| Elasticity Imaging Techniques | 1 | 2016 | 194 | 0.14 | Why? |
| Androgens | 3 | 2019 | 267 | 0.13 | Why? |
| Humans | 42 | 2021 | 930598 | 0.13 | Why? |
| Cardiotoxicity | 1 | 2017 | 365 | 0.13 | Why? |
| Insulin | 2 | 2019 | 1316 | 0.13 | Why? |
| Single-Blind Method | 1 | 2017 | 1283 | 0.13 | Why? |
| Genetic Testing | 1 | 2017 | 395 | 0.13 | Why? |
| Insulin Resistance | 1 | 2019 | 669 | 0.13 | Why? |
| Hyponatremia | 1 | 2017 | 371 | 0.13 | Why? |
| RNA, Long Noncoding | 1 | 2018 | 408 | 0.13 | Why? |
| Diabetic Nephropathies | 1 | 2017 | 315 | 0.13 | Why? |
| Adrenocorticotropic Hormone | 2 | 2003 | 107 | 0.12 | Why? |
| Sex Characteristics | 1 | 2020 | 1120 | 0.12 | Why? |
| Selenium | 1 | 2017 | 412 | 0.12 | Why? |
| Positron Emission Tomography Computed Tomography | 2 | 2018 | 1458 | 0.11 | Why? |
| Contrast Media | 1 | 2018 | 1011 | 0.11 | Why? |
| Body Weight | 1 | 2017 | 1074 | 0.11 | Why? |
| Nephrology | 1 | 2017 | 546 | 0.11 | Why? |
| Glycated Hemoglobin A | 1 | 2019 | 1316 | 0.11 | Why? |
| Proteins | 1 | 2019 | 921 | 0.11 | Why? |
| Molecular Targeted Therapy | 1 | 2020 | 1579 | 0.11 | Why? |
| Mice | 7 | 2019 | 21357 | 0.11 | Why? |
| Neurosurgical Procedures | 2 | 2019 | 1738 | 0.10 | Why? |
| Antiviral Agents | 3 | 2020 | 41703 | 0.10 | Why? |
| Adipocytes | 2 | 2018 | 173 | 0.10 | Why? |
| Organizational Innovation | 1 | 2020 | 2468 | 0.10 | Why? |
| Double-Blind Method | 2 | 2019 | 5988 | 0.10 | Why? |
| Middle Aged | 14 | 2021 | 270681 | 0.10 | Why? |
| Italy | 5 | 2020 | 38444 | 0.10 | Why? |
| Pneumonia, Viral | 5 | 2020 | 243684 | 0.10 | Why? |
| Sexual Behavior | 1 | 2019 | 1322 | 0.10 | Why? |
| Coronavirus Infections | 5 | 2020 | 253789 | 0.10 | Why? |
| Body Mass Index | 2 | 2019 | 4306 | 0.09 | Why? |
| Early Diagnosis | 1 | 2018 | 2443 | 0.09 | Why? |
| Aged | 12 | 2021 | 215776 | 0.09 | Why? |
| Heart Defects, Congenital | 1 | 2018 | 933 | 0.09 | Why? |
| Signal Transduction | 3 | 2020 | 7207 | 0.09 | Why? |
| Consensus | 2 | 2020 | 6345 | 0.09 | Why? |
| Gene Expression | 1 | 2018 | 3332 | 0.09 | Why? |
| Cystic Fibrosis | 1 | 2017 | 1104 | 0.09 | Why? |
| Treatment Outcome | 5 | 2020 | 51732 | 0.08 | Why? |
| Blood Glucose | 2 | 2019 | 3642 | 0.08 | Why? |
| Adult | 14 | 2019 | 244371 | 0.08 | Why? |
| Disease Models, Animal | 3 | 2019 | 10998 | 0.08 | Why? |
| Female | 19 | 2021 | 380317 | 0.08 | Why? |
| Hyperglycemia | 1 | 2017 | 1363 | 0.08 | Why? |
| Prospective Studies | 5 | 2019 | 43301 | 0.08 | Why? |
| Macrophages | 1 | 2018 | 2784 | 0.08 | Why? |
| Diagnostic Tests, Routine | 1 | 2017 | 2643 | 0.07 | Why? |
| Drug Therapy, Combination | 1 | 2019 | 7268 | 0.07 | Why? |
| Early Detection of Cancer | 1 | 2017 | 1956 | 0.07 | Why? |
| Ultrasonography | 3 | 2019 | 4409 | 0.07 | Why? |
| Dietary Supplements | 1 | 2017 | 2251 | 0.07 | Why? |
| Predictive Value of Tests | 2 | 2017 | 9537 | 0.07 | Why? |
| MicroRNAs | 1 | 2017 | 1787 | 0.07 | Why? |
| alpha-MSH | 1 | 2003 | 17 | 0.07 | Why? |
| Betacoronavirus | 4 | 2020 | 204454 | 0.07 | Why? |
| Young Adult | 7 | 2019 | 93724 | 0.06 | Why? |
| Corticotropin-Releasing Hormone | 1 | 2002 | 15 | 0.06 | Why? |
| Cyclic AMP | 2 | 2018 | 76 | 0.06 | Why? |
| Metabolic Syndrome | 1 | 2010 | 810 | 0.06 | Why? |
| Atherosclerosis | 1 | 2010 | 768 | 0.06 | Why? |
| Animals | 8 | 2019 | 78931 | 0.06 | Why? |
| Magnetic Resonance Imaging | 2 | 2018 | 6551 | 0.06 | Why? |
| Diagnosis, Differential | 1 | 2016 | 7220 | 0.06 | Why? |
| Cell Differentiation | 2 | 2018 | 1338 | 0.06 | Why? |
| Leptin | 1 | 2003 | 141 | 0.06 | Why? |
| Lung Neoplasms | 1 | 2018 | 3228 | 0.06 | Why? |
| Hormone Antagonists | 1 | 2020 | 29 | 0.06 | Why? |
| Medical Oncology | 1 | 2017 | 3826 | 0.05 | Why? |
| Time-to-Treatment | 1 | 2018 | 5883 | 0.05 | Why? |
| Postoperative Complications | 1 | 2019 | 5861 | 0.05 | Why? |
| Clinical Trials as Topic | 1 | 2020 | 7330 | 0.05 | Why? |
| Sphenoid Bone | 1 | 2019 | 13 | 0.05 | Why? |
| Obesity | 2 | 2018 | 7388 | 0.05 | Why? |
| Sex Hormone-Binding Globulin | 1 | 2019 | 57 | 0.05 | Why? |
| Cell Proliferation | 2 | 2018 | 1973 | 0.05 | Why? |
| Follicle Stimulating Hormone | 1 | 2019 | 73 | 0.05 | Why? |
| Rats | 2 | 2018 | 2764 | 0.05 | Why? |
| Host-Pathogen Interactions | 1 | 2020 | 11041 | 0.05 | Why? |
| Pandemics | 6 | 2020 | 389249 | 0.05 | Why? |
| Ovary | 1 | 2000 | 133 | 0.05 | Why? |
| Luteinizing Hormone | 1 | 2019 | 91 | 0.05 | Why? |
| Reproducibility of Results | 1 | 2016 | 11304 | 0.05 | Why? |
| MEF2 Transcription Factors | 1 | 2018 | 8 | 0.05 | Why? |
| Transcription Factor AP-2 | 1 | 2018 | 9 | 0.05 | Why? |
| LIM-Homeodomain Proteins | 1 | 2018 | 7 | 0.05 | Why? |
| Semen Analysis | 1 | 2020 | 235 | 0.05 | Why? |
| Triazenes | 1 | 2018 | 5 | 0.05 | Why? |
| Reference Values | 1 | 2002 | 795 | 0.05 | Why? |
| Adipogenesis | 1 | 2018 | 38 | 0.05 | Why? |
| Thrombosis | 1 | 2021 | 7504 | 0.05 | Why? |
| Comorbidity | 2 | 2021 | 34796 | 0.05 | Why? |
| Morphogenesis | 1 | 2018 | 43 | 0.05 | Why? |
| T-Box Domain Proteins | 1 | 2018 | 62 | 0.05 | Why? |
| Synkinesis | 1 | 2017 | 1 | 0.05 | Why? |
| Diabetes Mellitus | 1 | 2021 | 8207 | 0.05 | Why? |
| Pituitary Hormones | 1 | 2017 | 6 | 0.05 | Why? |
| Cell Plasticity | 1 | 2018 | 75 | 0.05 | Why? |
| Gonadotropins | 1 | 2017 | 21 | 0.05 | Why? |
| Nitric Oxide Donors | 1 | 2018 | 53 | 0.05 | Why? |
| Organ Size | 1 | 2019 | 384 | 0.05 | Why? |
| Point Mutation | 1 | 2021 | 481 | 0.05 | Why? |
| Polycystic Ovary Syndrome | 1 | 2000 | 151 | 0.04 | Why? |
| Polyploidy | 1 | 2017 | 16 | 0.04 | Why? |
| Cell Polarity | 1 | 2018 | 85 | 0.04 | Why? |
| Stromal Cells | 1 | 2018 | 105 | 0.04 | Why? |
| Paraganglioma | 1 | 2017 | 33 | 0.04 | Why? |
| Cytosol | 1 | 2017 | 77 | 0.04 | Why? |
| Gene Expression Regulation, Developmental | 1 | 2018 | 159 | 0.04 | Why? |
| NIH 3T3 Cells | 1 | 2017 | 147 | 0.04 | Why? |
| Subcutaneous Fat | 1 | 2018 | 94 | 0.04 | Why? |
| Time Factors | 2 | 2018 | 31397 | 0.04 | Why? |
| Estradiol | 1 | 2019 | 250 | 0.04 | Why? |
| Embryo, Mammalian | 1 | 2017 | 86 | 0.04 | Why? |
| Germ-Line Mutation | 1 | 2017 | 86 | 0.04 | Why? |
| Genome, Human | 1 | 2021 | 400 | 0.04 | Why? |
| Prognosis | 2 | 2017 | 32490 | 0.04 | Why? |
| Adolescent | 5 | 2019 | 86841 | 0.04 | Why? |
| Magnetite Nanoparticles | 1 | 2018 | 109 | 0.04 | Why? |
| Aged, 80 and over | 5 | 2019 | 88759 | 0.04 | Why? |
| Mice, Inbred C57BL | 2 | 2018 | 5542 | 0.04 | Why? |
| Age Factors | 1 | 2018 | 21039 | 0.04 | Why? |
| Phenotype | 2 | 2018 | 4037 | 0.04 | Why? |
| Quality of Life | 1 | 2017 | 9820 | 0.04 | Why? |
| Cells, Cultured | 2 | 2018 | 5835 | 0.04 | Why? |
| Organometallic Compounds | 1 | 2018 | 206 | 0.04 | Why? |
| Critical Illness | 1 | 2020 | 17281 | 0.04 | Why? |
| Protein Isoforms | 1 | 2017 | 347 | 0.04 | Why? |
| Cell Cycle | 1 | 2017 | 329 | 0.04 | Why? |
| Macrophage Activation | 1 | 2018 | 315 | 0.04 | Why? |
| Severity of Illness Index | 2 | 2021 | 48226 | 0.04 | Why? |
| Intra-Abdominal Fat | 1 | 2018 | 227 | 0.04 | Why? |
| Practice Guidelines as Topic | 1 | 2020 | 15421 | 0.04 | Why? |
| Microscopy, Electron | 1 | 2018 | 830 | 0.04 | Why? |
| Down-Regulation | 1 | 2021 | 1416 | 0.04 | Why? |
| Thyrotropin | 1 | 2017 | 262 | 0.04 | Why? |
| Thyroid Hormones | 1 | 2017 | 213 | 0.04 | Why? |
| Arginine | 1 | 2017 | 377 | 0.04 | Why? |
| Albumins | 1 | 2017 | 324 | 0.04 | Why? |
| Sexual Health | 1 | 2020 | 419 | 0.03 | Why? |
| Cell Nucleus | 1 | 2017 | 399 | 0.03 | Why? |
| Cell Line | 3 | 2018 | 12040 | 0.03 | Why? |
| Receptors, Urokinase Plasminogen Activator | 1 | 2017 | 252 | 0.03 | Why? |
| Transfection | 1 | 2017 | 864 | 0.03 | Why? |
| Cloning, Molecular | 1 | 2017 | 1036 | 0.03 | Why? |
| Gene Expression Regulation, Enzymologic | 1 | 2017 | 436 | 0.03 | Why? |
| Asia | 1 | 2021 | 2399 | 0.03 | Why? |
| Radiopharmaceuticals | 1 | 2018 | 763 | 0.03 | Why? |
| Blood Pressure | 2 | 2018 | 2198 | 0.03 | Why? |
| Mice, Knockout | 1 | 2018 | 1815 | 0.03 | Why? |
| Genetic Predisposition to Disease | 2 | 2018 | 4027 | 0.03 | Why? |
| Europe | 2 | 2021 | 12702 | 0.03 | Why? |
| Gestational Age | 1 | 2018 | 1488 | 0.03 | Why? |
| Societies, Medical | 2 | 2020 | 6907 | 0.03 | Why? |
| Transcription Factors | 1 | 2018 | 784 | 0.03 | Why? |
| Healthy Volunteers | 1 | 2017 | 1444 | 0.03 | Why? |
| Case-Control Studies | 2 | 2021 | 17671 | 0.03 | Why? |
| Overweight | 1 | 2017 | 916 | 0.03 | Why? |
| Epigenesis, Genetic | 1 | 2017 | 711 | 0.03 | Why? |
| Glomerular Filtration Rate | 1 | 2017 | 1262 | 0.03 | Why? |
| Creatinine | 1 | 2017 | 1443 | 0.03 | Why? |
| Waist Circumference | 1 | 2010 | 199 | 0.03 | Why? |
| Follow-Up Studies | 2 | 2019 | 17020 | 0.02 | Why? |
| Troponin I | 1 | 2018 | 1298 | 0.02 | Why? |
| Risk Factors | 4 | 2021 | 71621 | 0.02 | Why? |
| Fluorodeoxyglucose F18 | 1 | 2017 | 1153 | 0.02 | Why? |
| Recovery of Function | 1 | 2019 | 2461 | 0.02 | Why? |
| Gene Expression Regulation | 2 | 2017 | 4020 | 0.02 | Why? |
| Hemodynamics | 1 | 2017 | 1562 | 0.02 | Why? |
| Flow Cytometry | 1 | 2017 | 2393 | 0.02 | Why? |
| High-Throughput Screening Assays | 1 | 2017 | 1783 | 0.02 | Why? |
| Apoptosis | 1 | 2018 | 2335 | 0.02 | Why? |
| Polymorphism, Single Nucleotide | 1 | 2021 | 3607 | 0.02 | Why? |
| ROC Curve | 1 | 2019 | 6024 | 0.02 | Why? |
| Body Composition | 1 | 2010 | 414 | 0.02 | Why? |
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2017 | 1573 | 0.02 | Why? |
| Liver Cirrhosis | 1 | 2017 | 1810 | 0.02 | Why? |
| Neurology | 1 | 2017 | 1613 | 0.02 | Why? |
| Glycerol-3-Phosphate Dehydrogenase (NAD+) | 1 | 2003 | 1 | 0.02 | Why? |
| Glycerolphosphate Dehydrogenase | 1 | 2003 | 2 | 0.02 | Why? |
| Pro-Opiomelanocortin | 1 | 2003 | 6 | 0.02 | Why? |
| 3T3-L1 Cells | 1 | 2003 | 29 | 0.02 | Why? |
| Receptors, Leptin | 1 | 2003 | 12 | 0.02 | Why? |
| Receptor, Melanocortin, Type 1 | 1 | 2003 | 11 | 0.02 | Why? |
| HEK293 Cells | 1 | 2017 | 8394 | 0.02 | Why? |
| Kidney | 1 | 2017 | 3648 | 0.02 | Why? |
| Spain | 1 | 2021 | 15545 | 0.01 | Why? |
| Cell Lineage | 1 | 2003 | 241 | 0.01 | Why? |
| Pituitary Function Tests | 1 | 2000 | 2 | 0.01 | Why? |
| Kidney Failure, Chronic | 1 | 2017 | 3222 | 0.01 | Why? |
| Pituitary Gland | 1 | 2000 | 65 | 0.01 | Why? |
| Olfaction Disorders | 1 | 2017 | 3704 | 0.01 | Why? |
| Registries | 1 | 2018 | 12327 | 0.01 | Why? |
| Estrogens | 1 | 2000 | 252 | 0.01 | Why? |
| Critical Care | 1 | 2021 | 14081 | 0.01 | Why? |
| Prevalence | 1 | 2017 | 25773 | 0.01 | Why? |
| Hypertension | 1 | 2017 | 8895 | 0.01 | Why? |
| United States | 1 | 2021 | 46150 | 0.01 | Why? |
| Cohort Studies | 1 | 2017 | 36005 | 0.01 | Why? |
| Dose-Response Relationship, Drug | 1 | 2003 | 3776 | 0.01 | Why? |
| Peptide Fragments | 1 | 2003 | 2075 | 0.01 | Why? |
| Retrospective Studies | 1 | 2019 | 105322 | 0.01 | Why? |
| Child | 1 | 2017 | 70012 | 0.01 | Why? |
| Models, Biological | 1 | 2003 | 4907 | 0.00 | Why? |